Welcome to our dedicated page for Harvard Biosci news (Ticker: HBIO), a resource for investors and traders seeking the latest updates and insights on Harvard Biosci stock.
Harvard Bioscience, Inc. (HBIO) delivers specialized scientific instruments that power breakthroughs in life sciences research and drug discovery. This dedicated news hub provides investors and researchers with essential updates on corporate developments shaping the preclinical research sector.
Access authoritative coverage of HBIO's financial announcements, product innovations, and strategic initiatives. Our curated collection includes earnings reports, regulatory filings, technology launches, and partnership updates – all critical for assessing the company's role in advancing laboratory science worldwide.
Key updates span electrophysiology platform enhancements, telemetry system deployments, and organoid research advancements. Track how HBIO's global distribution network supports pharmaceutical developers and academic institutions through reliable instrumentation solutions.
Bookmark this page for streamlined monitoring of Harvard Bioscience's operational milestones. Verify research trends and corporate health through primary-source updates from the company's investor relations communications and verified media coverage.
Harvard Bioscience (Nasdaq: HBIO) has announced its participation in the Sidoti Small Cap Virtual Conference on September 18th, 2024. Jim Green, Chairman and CEO, and Jennifer Cote, CFO, will represent the company with a presentation scheduled for 9:15 am ET.
The presentation will be webcast live through the investor relations section of Harvard Bioscience's website. A replay will be available shortly after the presentation concludes. Interested parties can schedule one-on-one meetings through the conference organizers.
This event provides an opportunity for investors to gain insights into Harvard Bioscience's operations and future prospects directly from its top executives.
Harvard Bioscience (NASDAQ: HBIO) reported challenging Q2 2024 financial results. Revenues decreased to $23.1 million from $28.8 million in Q2 2023. The company experienced a net loss of $2.9 million, compared to a $1.0 million loss in the same period last year. Gross margin slightly declined to 57.2% from 58.0%.
Adjusted EBITDA fell to $1.3 million from $3.9 million in Q2 2023. The company implemented cost-saving measures expected to yield $4 million in annualized savings. Due to delayed market recovery, Harvard Bioscience reduced its 2024 revenue outlook to $97-102 million, with an expected gross margin of 59-60% and adjusted EBITDA margin in high single digits.
Harvard Bioscience (Nasdaq: HBIO) has announced its schedule for the second quarter 2024 earnings conference call, set for August 8, 2024, at 10:00 AM ET. The company will release its financial results for the quarter ended June 30, 2024, before the market opens on the same day. Interested participants can register for the call to ask questions, while an audio-only webcast option is also available. Financial information, including the earnings release and a related slide presentation, will be accessible on the Investor Relations section of Harvard Bioscience's website.
Harvard Bioscience (Nasdaq: HBIO) will present and host one-on-one meetings at the 14th Annual East Coast IDEAS Conference in New York City on June 12, 2024. Chairman and CEO Jim Green, along with CFO Jennifer Cote, will address investors from 2:45-3:20 PM ET at the Jay Conference Center – Bryant Park. The presentation will be webcast live and accessible via the company's investor relations website, with a replay available shortly afterward. To schedule individual meetings, investors should contact the conference team at Three Part Advisors.
Harvard Bioscience announced that CEO Jim Green and CFO Jennifer Cote will present at the Jefferies Global Healthcare Conference on June 5, 2024.
The event will be held at the Marriott Marquis, New York City, from 2:00 to 2:25 PM Eastern Time.
The presentation will be webcast live via the Harvard Bioscience investor relations website, with a replay available afterwards.
Additionally, the company will host one-on-one meetings with investors during the conference.
For scheduling these meetings, investors can contact healthcareconference@jefferies.com.
Harvard Bioscience announced that its CEO, Jim Green, and CFO, Jennifer Cote, will participate in the Benchmark Healthcare House Call Virtual Conference on May 22, 2024. The event will feature a live fireside chat from 9:00-9:40 am ET and one-on-one meetings with investors. Interested parties can register for the presentation or schedule meetings via the Benchmark website.
Harvard Bioscience, Inc. (Nasdaq: HBIO) announced its first quarter 2024 financial results, reporting revenues of $24.5 million, a gross margin of 60.3%, and adjusted EBITDA of $1.6 million. Despite challenges in certain markets, the company remains focused on efficiency and growth, with a cost reduction initiative in place. The net loss for the quarter was $(4.7) million, with a decrease in revenues compared to the prior year. The company expects flat revenues for 2024, with second-half growth and a gross margin of 60%. Harvard Bioscience will be hosting a conference call to discuss the results.
Harvard Bioscience, Inc. (Nasdaq: HBIO) will release its first quarter 2024 financial results on May 7, 2024. The company will hold a conference call at 8:00 AM ET to discuss the results. Participants can register to join the call and ask questions. Financial information will be accessible on the Investor Relations section of Harvard Bioscience's website.
FAQ
What is the current stock price of Harvard Biosci (HBIO)?
What is the market cap of Harvard Biosci (HBIO)?
